“Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient With Stage III RenalCell Carcinoma”. 2026. Journal of Kidney Cancer 13 (2): 21-28. https://doi.org/10.15586/jkcvhl.v13i2.455.